依替必利 | 84226-12-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 依替必利
• 英文名称: eticlopride
• 英文别名: S-(-)-eticlopride hydrochloride；S(-)-eticlopride；5-chloro-3-ethyl-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2-hydroxy-6-methoxybenzamide
• CAS: 84226-12-0
• 化学式: C₁₇H₂₅ClN₂O₃
• 分子量: 340.85
• InChiKey: AADCDMQTJNYOSS-LBPRGKRZSA-N

物化性质

• 溶解度：
  在水中的溶解度12 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  61.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• WGK Germany：
  3
• RTECS号：
  CV2450000

反应信息

• 作为产物：
  描述：

  3-Chloro-5-ethyl-N-((S)-1-ethyl-pyrrolidin-2-ylmethyl)-2,6-dimethoxy-benzamide 在 盐酸 、 三溴化硼 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 1.5h， 生成 依替必利 、 Isoeticlopride
  参考文献：
  名称：

  潜在的抗精神病药。4.化学，行为药理学和对3，5-二取代的N-[（1-乙基-2-吡咯烷基）甲基] -6-甲氧基水杨酰胺的[3H] spiperone结合的抑制。

  摘要：

  从2,6-二甲氧基苯甲酸开始，通过相应的3,5-硼的三溴化硼脱甲基，合成了一系列的3,5-二取代的N-[（（1-乙基-2-吡咯烷基）甲基] -6-甲氧基水杨酰胺。二取代2，6-二甲氧基苯甲酰胺和两个位置异构体的分离。正确的结构分配基于对它们的13C NMR光谱进行的选择性去偶联研究。水杨酰胺衍生物通过在大鼠中抑制阿扑吗啡综合征的能力在体内进行了抗多巴胺活性的测试，并在体外从大鼠脑纹状体制剂中置换了[3H]哌酮的能力进行了体外抗多巴胺活性的测试。该活性似乎仅存在于S对映异构体中。几种化合物比氟哌啶醇更有效，特别是在芳环的3-位具有乙基且在5-位具有卤原子的那些。相应的5-烷基-3-卤素取代的化合物的活性低得多。发现最有效的化合物的急性毒性低。一些水杨酰胺在阻止阿扑吗啡诱导的过度活跃和阻止阿朴吗啡引起的刻板印象的剂量之间显示出10-20倍的间隔。一种化合物S-（-）-3,5-二氯-N-[（（1-乙基-2-吡咯烷基）甲基]

  DOI：

  10.1021/jm00151a010

文献信息

• [EN] MULTIPLE D2 A(NTA)GONISTS/H3 ANTAGONISTS FOR TREATMENT OF CNS-RELATED DISORDERS<br/>[FR] MULTIPLES A(NTA)GONISTES DE D2/ANTAGONISTES DE H3 POUR LE TRAITEMENT DE TROUBLES ASSOCIÉS AU SNC
  申请人：AAPA B V

  公开号：WO2015069110A1

  公开（公告）日：2015-05-14

  The present invention relates to compounds compound according to Formula (III); and pharmaceutically acceptable salts, hydrates and solvates thereof. These compounds have D2receptor antagonist/(partial) agonist effects and H3antagonistic effects, pharmaceutical compositions thereof, and methods of using them for application in the prophylaxis or treatment of CNS disorders.

  本发明涉及按照式（III）的化合物；以及其药学上可接受的盐、水合物和溶剂合物。这些化合物具有D2受体拮抗/(部分)激动剂效应和H3拮抗效应，以及其药物组合物，以及将其用于预防或治疗中枢神经系统疾病的方法。
• DRUG DERIVATIVES
  申请人：Craighead Mark

  公开号：US20130225594A1

  公开（公告）日：2013-08-29

  The present invention relates to derivatives of known active pharmaceutical compounds. These derivatives are differentiated from the parent active compound by virtue of being redox derivatives of the active compound. This means that one or more of the functional groups in the active compound has been converted to another group in one or more reactions which may be considered to represent a change of oxidation state. We refer to these compounds generally as redox derivatives. The derivatives of the invention may be related to the original parent active pharmaceutical compound by only a single step transformation, or may be related via several synthetic steps including one or more changes of oxidation state. In certain cases, the functional group obtained after two or more transformations may be in the same oxidation state as the parent active compound (and we include these compounds in our definition of redox derivatives). In other cases, the oxidation state of the derivative of the invention may be regarded as being different from that of the parent compound. In many cases, the compounds of the invention have inherent therapeutic activity on their own account. In some cases, this activity relative to the same target or targets of the parent compound is as good as or better than the activity which the parent compound has against the target or targets.

  本发明涉及已知活性药物化合物的衍生物。这些衍生物通过是活性化合物的氧化还原衍生物与母体活性化合物相区别。这意味着活性化合物中的一个或多个官能团已转化为另一组，在一项或多项反应中，这可以被认为代表氧化态的变化。我们通常将这些化合物称为氧化还原衍生物。发明中的衍生物可能与原始母体活性药物化合物仅通过单一步骤转换有关，或者可能通过包括一个或多个氧化态变化的几个合成步骤与之相关。在某些情况下，经过两个或更多转换后获得的官能团可能与母体活性化合物处于相同的氧化态（我们将这些化合物包括在我们的氧化还原衍生物定义中）。在其他情况下，发明的衍生物的氧化态可以被认为是与母体化合物不同的。在许多情况下，发明中的化合物本身就具有固有的治疗活性。在某些情况下，相对于母体化合物的相同靶点或靶点，这种活性与母体化合物针对该靶点或靶点的活性一样好或更好。
• [EN] SUBSTITUTED 3-PHENOXYAZETIDIN-1-YL-PYRAZINES HAVING GPR52 AGONISTIC ACTIVITY<br/>[FR] 3-PHÉNOXYAZÉTIDIN-1-YL-PYRAZINES SUBSTITUÉES AYANT UNE ACTIVITÉ AGONISTE DE GPR52
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2021198149A1

  公开（公告）日：2021-10-07

  The invention relates to substituted 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) which are agonists of GPR52, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to the 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) for use as a medicament, pharmaceutical compositions comprising the 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) and processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.

  该发明涉及一般式(I)的取代3-苯氧基氮杂环丙氮-1-基吡嗪，它们是GPR52的激动剂，可用于治疗中枢神经系统疾病和其他疾病。此外，该发明涉及一般式(I)的3-苯氧基氮杂环丙氮-1-基吡嗪作为药物的用途，包括含有一般式(I)的3-苯氧基氮杂环丙氮-1-基吡嗪的药物组合物，以及制备药物组合物的方法以及根据该发明制造化合物的方法。
• [EN] DOPAMINE D2 RECEPTOR LIGANDS<br/>[FR] LIGANDS DES RÉCEPTEURS DOPAMINERGIQUES D2
  申请人：BROAD INST INC

  公开号：WO2016100940A1

  公开（公告）日：2016-06-23

  The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity. The present invention relates to novel compounds that modulate dopamine D2 receptors. In particular, compounds of the present invention show functional selectivity at the dopamine D2 receptors and exhibit selectivity downstream of the D2 receptors, on the 0- arrestin pathway and/or on the cAMP pathway.

  本发明涉及新型多巴胺D2受体配体。该发明进一步涉及功能偏向的多巴胺D2受体配体以及利用这些化合物治疗或预防与多巴胺活性失调相关的中枢神经系统和全身性疾病。本发明涉及调节多巴胺D2受体的新型化合物。具体而言，本发明的化合物在多巴胺D2受体上显示功能选择性，并在D2受体下游、0-阿雷斯汀途径和/或cAMP途径上表现出选择性。
• Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof
  申请人：——

  公开号：US20030105071A1

  公开（公告）日：2003-06-05

  One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various mammalian cellular receptors, including G-protein coupled receptors. A third aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for mammalian dopamine, muscarinic or serotonin receptors or transporters. Another aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for mammalian dopamine, muscarinic or serotonin receptors. The compounds of the present invention will also find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, analgesia, schizophrenia, Parkinson's disease, restless leg syndrome, sleeping disorders, attention deficit hyperactivity disorder, irritable bowel syndrome, premature ejaculation, menstrual dysphoria syndrome, urinary incontinence, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, Tourette's syndrome, psychiatric disorders, stroke, senile dementia, peptic ulcers, pulmonary obstruction disorders, and asthma.

  本发明的一个方面涉及新颖的杂环化合物。本发明的第二个方面涉及将这些新颖的杂环化合物用作各种哺乳动物细胞受体的配体，包括G蛋白偶联受体。本发明的第三个方面涉及将这些新颖的杂环化合物用作哺乳动物多巴胺、肌肉或血清素受体或转运体的配体。本发明的另一个方面涉及将这些新颖的杂环化合物用作哺乳动物多巴胺、肌肉或血清素受体的配体。本发明的化合物还将用于治疗许多困扰哺乳动物的疾病、症状和疾病，包括但不限于成瘾、焦虑、抑郁、性功能障碍、高血压、偏头痛、阿尔茨海默病、肥胖、呕吐、精神病、镇痛、精神分裂症、帕金森病、不宁腿综合征、睡眠障碍、注意力缺陷多动障碍、肠易激综合征、早泄、月经痛综合征、尿失禁、炎症性疼痛、神经痛、Lesche-Nyhane病、威尔逊病、抽动症、精神障碍、中风、老年性痴呆、消化性溃疡、肺阻塞疾病和哮喘。